|

NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC

RECRUITINGPhase 2Sponsored by Chongqing University Cancer Hospital
Actively Recruiting
PhasePhase 2
SponsorChongqing University Cancer Hospital
Started2025-10-16
Est. completion2027-10-01
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted

Summary

This is a prospective, randomized, multicenter phase II trial evaluating neoadjuvant CAPOX chemotherapy combined with the PD-1 inhibitor serplulimab administered either before or after short-course radiotherapy (SCRT) in patients with locally advanced rectal cancer. The primary endpoint is the complete response (CR) rate, defined as pathological complete response (pCR) plus clinical complete response (cCR). Secondary endpoints include safety, perioperative outcomes, survival, recurrence patterns, and integrated multi-omics analyses of paired tumor samples. The study aims to determine the optimal sequencing strategy and identify immune microenvironmental biomarkers predictive of response.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-70 years, any sex.
* Clinical stage II/III rectal adenocarcinoma (cT3-T4N0 or cT2-T4N+, M0) according to AJCC 8th edition.
* Tumor located ≤10 cm from anal verge (confirmed by colonoscopy or digital rectal exam).
* Histologically confirmed rectal adenocarcinoma.
* ECOG performance status 0-1.
* Adequate organ function:
* Hemoglobin ≥90 g/L; WBC ≥3.5×10⁹/L; ANC ≥1.5×10⁹/L; Platelets ≥100×10⁹/L.
* Serum creatinine, BUN ≤1.0×ULN.
* ALT, AST, ALP ≤1.5×ULN; Total bilirubin ≤1.5×ULN.
* Negative urine protein; normal coagulation.
* No known allergy to fluoropyrimidines or platinum.
* No prior surgery (except diverting colostomy), chemotherapy, or radiotherapy for primary rectal cancer.
* No prior pelvic radiotherapy.
* Signed written informed consent.

Exclusion Criteria:

* Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors, or other investigational immunotherapies.
* Active autoimmune disease (e.g., Crohn's disease, ulcerative colitis, rheumatoid arthritis, scleroderma, SLE, vasculitis).
* Symptomatic interstitial lung disease or active pneumonia.
* GI conditions increasing risk of perforation (e.g., active diverticulitis, abscess, obstruction).
* History of other malignancies, except cured non-melanoma skin cancer or in situ cervical cancer.
* Active infections, uncontrolled heart failure, recent myocardial infarction (\<6 months), unstable angina, or severe arrhythmia.
* Other uncontrolled disease or condition that may interfere with study participation.
* Pregnancy or lactation.
* Known immunodeficiency (e.g., HIV) or history of organ/allo-HSCT transplantation.
* Active HBV (HBV DNA ≥2000 IU/mL), HCV infection, or active tuberculosis.
* Receipt of cancer vaccines or live vaccines within 4 weeks prior to enrollment (seasonal inactivated influenza vaccines allowed).
* Concurrent use of other investigational agents, long-term corticosteroids, or immunosuppressants.
* Psychiatric disorders, substance abuse, or social conditions limiting compliance.
* Known allergy or contraindication to study drugs.

Conditions3

CancerLocally Advanced Rectal Cancer (LARC)Rectal Cancer Patients

Interventions2

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.